Intermittent hypoxia and adipose tissue - Insight into the pathophysiology of the Obstructive Sleep Apnoea Syndrome (OSAS) and treatment options

The purpose of the Seminar was to discuss in a highly multidisciplinary environment the relative role of obesity, OSAS or both in the pathogenesis of dyslipidemia, a well-known risk factor for cardiovascular disease. The topic is currently debated in the literature and has important therapeutic implications, given the controversial results of OSAS treatment on metabolic variables and the recent progress in the therapeutic approach to the obese patient. The Seminar could help increase the cooperation in research between the fields of obesity and OSAS in Europe.

Download all media

Introduction and epidemiology of dyslipidemia in OSAS patients M. Bonsignore (Palermo, Italy)
Data from animal models: role of IH and obesity V. Polotsky (Baltimore, United States of America)
Visceral adipose tissue as a target for therapeutic intervention: an update F. Giorgino (Bari, Italy)
Effects of OSA on metabolic dysfunction in children L. Kheirandish-Gozal (Chicago, USA)
Effects of OSA on metabolic dysfunction in adolescents - is OSA relevant for adolescent obesity? S. Verhulst (Wilrijk, Belgium)
Does sleep loss play a role in adipose tissue dysfunction? C. Philipps (Sydney, Australia)
Inflammation in obese adipose tissue S. Sasson (Jerusalem, Israel)
Genetic factors: OSAS, obesity or both? R. L. Riha (Edinburgh, United Kingdom), T. Gislason (Reykjavik, Iceland)
CPAP treatment: effects on plasma lipids and liver function V. Polotsky (Baltimore, MD, USA)